NeoGenomics is delivering its earnings result tonight with the sharpest short position in months sitting opposite a Street that just moved materially higher on its targets.
The positioning story is the most charged it has been in this cycle. Short interest has climbed to 10.2% of the free float — up 18% on the week and 22% over the past month, the sharpest multi-week build since at least June. The near-term history makes the timing clear: shorts were running around 8.7% of float in mid-June, crossed 10% around July 23, and have held there through the print. Despite that build, the lending market remains relaxed. Availability is running at 346% of outstanding short interest — meaning more than three shares are available to borrow for every one already out — and the cost to borrow is a negligible 0.51%. Bears have put on size heading into tonight, but they are not paying for the privilege and the pool is not anywhere near stressed.
Options traders have turned more defensive than usual at precisely the wrong moment to be defensive. The put/call ratio jumped to 0.052 on Tuesday — more than 2.6 standard deviations above its 20-day average of 0.015 — a spike that stands out sharply against a PCR that spent most of July below 0.011. That is a meaningful shift in hedging demand, and it arrived as the stock was already giving back ground. NEO closed at $13.40, off 7% on the week and 5% over the past month. Close peers and shed roughly 6% apiece over the same five sessions, suggesting sector-wide pressure rather than a NEO-specific de-rating. was the outlier, gaining 2% on the week.
The Street disagrees sharply with the bears, and the disagreement intensified in the 48 hours before tonight's print. Needham's Mike Matson lifted his target to $19 from $15 this morning while maintaining a Buy — a 27% upgrade to his price objective published same-day as the earnings release. That follows Benchmark raising its target to $16 from $11 last Friday. Both actions build on a wave of positive analyst revision that started in late April, when Leerink Partners upgraded the name to Outperform with a $25 target and Benchmark moved from Hold to Buy. The consensus now sits at six Buy-rated analysts, with a mean target of $18.83 against a current price of $13.40 — implying roughly 41% upside on the Street's base case. EPS momentum is the factor story: the 30-day and 90-day momentum ranks sit at the 89th and 94th percentiles respectively, reflecting a sustained run of upward estimate revisions. Bulls point to adjusted gross margin expanding 150 basis points to 46.8% and NGS revenue growing 18% in Q1 2025 as evidence of operating leverage building. Bears focus on non-clinical sales missing consensus at $18.3 million against an expected $20.9 million, reimbursement headwinds, and the risk of reinvestment demands compressing EBITDA margins.
The one prior earnings reaction in the dataset supports the bull case. After the May 2026 print, NEO gained 3.7% the following day and extended that to 14.5% over the subsequent five sessions — the last time the Street got new numbers, it re-rated the stock meaningfully higher. That said, the setup tonight is different: short interest was lower then, the PCR spike had not yet occurred, and the stock enters this print from a weaker base after the week's sell-off.
What to watch is whether tonight's revenue per test and NGS revenue growth can hold the trajectory that drove the May rally — any deterioration in those two lines, against a short position now 18% larger than last week, would create an asymmetric test of how committed bears and bulls are at current levels.
See the live data behind this article on ORTEX.
Open NEO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
